Is tofacitinib a game-changing drug for ulcerative colitis?

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Fernando José Magro Dias

    Autor

Participantes de fora da FMUP

  • Estevinho, MM

Unidades de investigação

Abstract

The increasing knowledge on ulcerative colitis' pathophysiology has contributed to the expansion of the therapeutic arsenal for this condition. However, to date, 25-40% of patients with ulcerative colitis remain primary or secondary non-responders to therapy, and up to 10% need to eventually undergo a colectomy. Janus kinase inhibitors block cytokine signalling involved in the pathogenesis of several inflammatory conditions. Tofacitinib is the first drug of this class approved for moderate-to-severely active ulcerative colitis in patients for whom disease worsened and those who did not improve with conventional therapy (aminosalicylates, corticosteroids and immunosuppressants) or monoclonal antibodies. We aimed to review the main aspects and concerns related to the current use of tofacitinib and to explore its future application.

Dados da publicação

ISSN/ISSNe:
2050-6406, 2050-6414

United European Gastroenterology Journal  John Wiley & Sons Inc.

Tipo:
Review
Páginas:
755-763
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 11

Citações Recebidas na Scopus: 13

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • Case report; inflammatory bowel disease; Janus kinase inhibitors; tofacitinib; ulcerative colitis

Proyectos asociados

Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal

Investigador Principal: Fernando José Magro Dias

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação